Literature DB >> 23239001

Population pharmacokinetics of naringin in total flavonoids of Drynaria fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis.

Jian-nong Wang1, Jun-jie Jiang, Yan-ming Xie, Xu Wei, Jian-peng Li, Jing-li Duan, Xin Xiong.   

Abstract

OBJECTIVE: To evaluate the effect of covariates on the pharmacokinetic profiles of naringin in the total flavonoids of Drynaria fortunei (Kunze) J. Sm. in the Qianggu Capsule () by evaluating Chinese women with primary osteoporosis.
METHODS: A total of 98 female patients from the communities of Jingshan, Beixinqiao, Jiaodaokou, Chaoyangmen, and Donghuamen in Beijing, China, aged 40 to 80 years, were included in this study. Blood samples were collected before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after a single oral dose of Qianggu Capsule. The concentration in blood samples from 32 patients before and 0.5, 1, 2, 3, and 4 h after drug administration were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and full set of pharmacokinetic data was analyzed with nonlinear mixed-effect modeling (NONMEM) software. The mean of population parameters clearance (C1), central distribution volume (V), absorption rate constant (Ka1), inter-compartmental clearance (C2), peripheral distribution volume (V2) were set as parameters and estimated through base model, covariate model, and final model. Age, height, weight, blood urea nitrogen (BUN), serum creatinine (Scr), alanine transaminase (ALT), aspartate transaminase (AST), hyperlipidemia, Liver (Gan) Kidney (Shen) yin insufficiency (GSYI), Kidney (Shen) yang insufficiency (SYI) were set as covariates.
RESULTS: The relationships between these parameters and covariates were analyzed. The results showed that C1 was the main parameter influenced by the selected covariates among the population parameters, and the relationships between the covariates and C1 were analyzed, among the selected covariates hyperlipidemia was identified as significant covariate of C1.
CONCLUSION: The pharmacokinetic behaviors of naringin are altered with hyperlipidemia in Chinese women with primary osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239001     DOI: 10.1007/s11655-012-1296-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  4 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  Determination of naringin and naringenin in human plasma by high-performance liquid chromatography.

Authors:  K Ishii; T Furuta; Y Kasuya
Journal:  J Chromatogr B Biomed Appl       Date:  1996-08-30

3.  Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction.

Authors:  K Ishii; T Furuta; Y Kasuya
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-12-19

4.  A rapid LC/MS/MS quantitation assay for naringin and its two metabolites in rats plasma.

Authors:  Tiezheng Fang; Yonggang Wang; Yan Ma; Weiwei Su; Yang Bai; Peiyu Zhao
Journal:  J Pharm Biomed Anal       Date:  2006-01-10       Impact factor: 3.935

  4 in total
  2 in total

Review 1.  Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine.

Authors:  Xu Wei; Aili Xu; Hao Shen; Yanming Xie
Journal:  BMC Complement Altern Med       Date:  2017-02-13       Impact factor: 3.659

2.  Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology.

Authors:  Guihong Liang; Jinlong Zhao; Yaoxing Dou; Yuan Yang; Di Zhao; Zhanpeng Zhou; Rui Zhang; Weiyi Yang; Lingfeng Zeng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.